Introduction: Crohn's disease (CD) and ulcerative colitis (UC) are characterized by persistent gastrointestinal inflammation. Timely, effective management is crucial for improving long-term patient outcomes.
Materials and methods: As part of the IBD-PODCAST study, this cross-sectional, multicenter, non-interventional study included 396 patients (196 CD, 200 UC) from 14 Spanish hospitals, aiming to assess treat-to-target implementation through monitoring practices in a real-world setting. Biochemical markers (CRP, fCal) measured within ±14 days of index date and imaging tests (endoscopy, IUS, MRI/MRE/CT) during the previous year were collected. Actions taken based on the results were evaluated.
Results: Biochemical markers were requested in more than half the patients and imaging in a third, including endoscopic procedures in 18.9% of CD and 28% of UC cases, and IUS in <12% of patients. Treatment was adjusted in 67% of CD patients with symptoms and 67% of UC patients with rectal bleeding. Only 39% of CD and 26% of UC patients with abnormal fCal had treatment modifications, with 35% and 37% undergoing additional monitoring, respectively. Endoscopic findings prompted adjustments in 87% of CD and 56% of UC patients.
Conclusion: The IBD-PODCAST study examines routine IBD management in Spain, highlighting the need for improved monitoring and intervention to optimize patient care and outcomes.